In late 2023, our founder was running a research protocol out of a small lab. She'd buy the same compound from three vendors, run her own HPLC on each, and find herself rejecting two out of three lots. The chromatograms came back ugly, the CoAs didn't match, and the explanations were always the same: “It's a different lot now.”
The problem wasn't bad chemistry — peptide synthesis is a hundred-year-old craft. The problem was the layer between chemists and customers: distributors who relabeled drum-shipped powder, marketing teams that hid the analytics behind a paywall, and a research market that had decided ambiguity was a feature.
So she called colleagues from Bachem and a third with deep CoA experience from a major contract testing lab. The three sketched a supplier on a napkin: own the synthesis, publish the data, ship the records. A year later, that napkin became the team you see today.
We're still small. We make ten compounds. Every vial leaves with two CoAs and the operator's name on the synthesis card. The records outlast the vial.
